QuantAnts Machines Discover Biomarkers for RAS Signaling Activation and Design sgRNAs for CRISPR to Target Complex CD9, CD34, and CD74
December 2022
in “
Research Square (Research Square)
”
Studysummary In this study, the researchers developed a quantum algorithm, QuantAnts machines, which identified complexes of CD9, CD34, and CD74 as potential targets for certain cancers involving the RAS pathway.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document introduces a quantum algorithm called QuantAnts machines for identifying biomarkers in oncology. This machine intelligence allows for the sampling of biomarker-verse for targeted RAS signaling activation, revealing combinations of biomarkers with therapeutic applications. The QuantAnts for Clinical Oncology model, ASCO(ant-4), identifies the complex CD9, CD34, and CD74 as targets for the RAS pathway in various cancer phenotypes. The model is further generalized for genetic code designs (QuantAnts-CRISPR), enabling optimized sgRNA for CRISPR-Cas9 to target the complex CD9, CD34, and CD74 simultaneously. The sgRNA designs are optimized by reversing mutation processes over the targeted complex.
